Deals· August 8, 2026 · 15 min read
Servier's $2.5B Day One deal: tovorafenib (Ojemda) & first EU JCA completion
By Ran Chen#Servier#Day One#Tovorafenib
Tovorafenib (Ojemda) type II pan-RAF inhibitor clinical data, FIREFLY-1 and FIREFLY-2 trial results, and pediatric low-grade glioma access.